These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23490158)

  • 1. Stapled peptide-based membrane fusion inhibitors of hepatitis C virus.
    Cui HK; Qing J; Guo Y; Wang YJ; Cui LJ; He TH; Zhang L; Liu L
    Bioorg Med Chem; 2013 Jun; 21(12):3547-54. PubMed ID: 23490158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81.
    Wagner CE; Mohler ML; Kang GS; Miller DD; Geisert EE; Chang YA; Fleischer EB; Shea KJ
    J Med Chem; 2003 Jul; 46(14):2823-33. PubMed ID: 12825926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.
    Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R
    Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel substituted pyrimidines as HCV replication (replicase) inhibitors.
    Kwong CD; Clark JL; Fowler AT; Geng F; Kezar HS; Roychowdhury A; Reynolds RC; Maddry JA; Ananthan S; Secrist JA; Shih NY; Piwinski JJ; Li C; Feld B; Huang HC; Tong X; George Njoroge F; Arasappan A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1160-4. PubMed ID: 22178556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
    Allander T; Forns X; Emerson SU; Purcell RH; Bukh J
    Virology; 2000 Nov; 277(2):358-67. PubMed ID: 11080483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    He S; Xiao J; Dulcey AE; Lin B; Rolt A; Hu Z; Hu X; Wang AQ; Xu X; Southall N; Ferrer M; Zheng W; Liang TJ; Marugan JJ
    J Med Chem; 2016 Feb; 59(3):841-53. PubMed ID: 26599718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
    Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
    J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helical peptides derived from lactoferrin bind hepatitis C virus envelope protein E2.
    Beleid R; Douglas D; Kneteman N; Kaur K
    Chem Biol Drug Des; 2008 Nov; 72(5):436-43. PubMed ID: 19012577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
    Wunschmann S; Muller HM; Stipp CS; Hemler ME; Stapleton JT
    J Infect Dis; 2006 Oct; 194(8):1058-67. PubMed ID: 16991080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
    Kronenberger B; Sarrazin C; Hofmann WP; von Wagner M; Herrmann E; Welsch C; Elez R; Rüster B; Piiper A; Zeuzem S
    J Viral Hepat; 2004 Jul; 11(4):310-8. PubMed ID: 15230853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81.
    Cao J; Liao XL; Wu SM; Zhao P; Zhao LJ; Wu WB; Qi ZT
    J Microbiol Methods; 2007 Mar; 68(3):601-4. PubMed ID: 17178166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*.
    Olenina LV; Kuzmina TI; Sobolev BN; Kuraeva TE; Kolesanova EF; Archakov AI
    J Viral Hepat; 2005 Nov; 12(6):584-93. PubMed ID: 16255759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of a novel 7-aminopyrazolo[1,5-a]pyrimidine analog as a potent hepatitis C virus inhibitor.
    Hwang JY; Windisch MP; Jo S; Kim K; Kong S; Kim HC; Kim S; Kim H; Lee ME; Kim Y; Choi J; Park DS; Park E; Kwon J; Nam J; Ahn S; Cechetto J; Kim J; Liuzzi M; No Z; Lee J
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7297-301. PubMed ID: 23159569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential role of the heparan sulfate in the hepatitis C virus attachment.
    Heo TH
    Acta Virol; 2008; 52(1):7-15. PubMed ID: 18459830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81.
    Cao J; Zhao P; Miao XH; Zhao LJ; Xue LJ; Qi Zt Zt
    Cell Res; 2003 Dec; 13(6):473-9. PubMed ID: 14728804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop.
    Nakajima H; Cocquerel L; Kiyokawa N; Fujimoto J; Levy S
    Biochem Biophys Res Commun; 2005 Mar; 328(4):1091-100. PubMed ID: 15707989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
    Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and anti-HCV activity evaluation of anilinoquinoline derivatives.
    Peng HK; Lin CK; Yang SY; Tseng CK; Tzeng CC; Lee JC; Yang SC
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1107-10. PubMed ID: 22204909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of peptides binding to HCV e2 and inhibiting viral infectivity.
    Hong HW; Lee SW; Myung H
    J Microbiol Biotechnol; 2010 Dec; 20(12):1769-71. PubMed ID: 21193836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.